PMID- 26944319
OWN - NLM
STAT- MEDLINE
DCOM- 20160829
LR  - 20160318
IS  - 1872-7980 (Electronic)
IS  - 0304-3835 (Linking)
VI  - 374
IP  - 2
DP  - 2016 May 1
TI  - Correlation between the radiation responses of fibroblasts cultured from
      individual patients and the risk of late reaction after breast radiotherapy.
PG  - 324-30
LID - 10.1016/j.canlet.2016.02.036 [doi]
LID - S0304-3835(16)30104-5 [pii]
AB  - Late normal tissue toxicity varies widely between patients and limits breast
      radiotherapy dose. Here we aimed to determine its relationship to DNA damage
      responses of fibroblast cultures from individual patients. Thirty-five breast
      cancer patients, with minimal or marked breast changes after breast-conserving
      therapy consented to receive a 4 Gy test irradiation to a small skin field of the
      left buttock and have punch biopsies taken from irradiated and unirradiated skin.
      Early-passage fibroblast cultures were established by outgrowth and irradiated in
      vitro with 0 or 4 Gy. 53BP1 foci, p53 and p21/CDKN1A were detected by
      immunofluorescence microscopy. Residual 53BP1 foci counts 24 h after in vitro
      irradiation were significantly higher in fibroblasts from RT-sensitive versus
      RT-resistant patients. Furthermore, significantly larger fractions of p53- but
      not p21/CDKN1A-positive fibroblasts were found in cultures from RT-sensitive
      patients without in vitro irradiation, and 2 h and 6 d post-irradiation.
      Exploratory analysis showed a stronger p53 response 2 h after irradiation of
      fibroblasts established from patients with severe reaction. These results
      associate the radiation response of fibroblasts with late reaction of the breast 
      after RT and suggest a correlation with severity.
CI  - Copyright (c) 2016 Elsevier Ireland Ltd. All rights reserved.
FAU - Nuta, Otilia
AU  - Nuta O
AD  - Public Health England, Centre for Radiation, Chemical and Environmental Hazards, 
      Chilton, UK.
FAU - Somaiah, Navita
AU  - Somaiah N
AD  - Division of Radiotherapy and Imaging, Institute of Cancer Research, London, UK.
FAU - Boyle, Sue
AU  - Boyle S
AD  - Division of Radiotherapy and Imaging, Institute of Cancer Research, London, UK.
FAU - Chua, Melvin Lee Kiang
AU  - Chua ML
AD  - Public Health England, Centre for Radiation, Chemical and Environmental Hazards, 
      Chilton, UK; National Cancer Centre, Singapore Duke-NUS Graduate Medical School, 
      11 Hospital Drive, Singapore, 169610.
FAU - Gothard, Lone
AU  - Gothard L
AD  - Division of Radiotherapy and Imaging, Institute of Cancer Research, London, UK.
FAU - Yarnold, John
AU  - Yarnold J
AD  - Division of Radiotherapy and Imaging, Institute of Cancer Research, London, UK.
FAU - Rothkamm, Kai
AU  - Rothkamm K
AD  - Public Health England, Centre for Radiation, Chemical and Environmental Hazards, 
      Chilton, UK; Department of Radiotherapy and Radiation Oncology, University
      Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany.
FAU - Herskind, Carsten
AU  - Herskind C
AD  - Department of Radiation Oncology, Universitaetsmedizin Mannheim, Medical Faculty 
      Mannheim, Heidelberg University, Mannheim, Germany. Electronic address:
      carsten.herskind@medma.uni-heidelberg.de.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160302
PL  - Ireland
TA  - Cancer Lett
JT  - Cancer letters
JID - 7600053
RN  - 0 (TP53 protein, human)
RN  - 0 (Tumor Suppressor Protein p53)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Breast Neoplasms/genetics/metabolism/pathology/*radiotherapy
MH  - Cells, Cultured
MH  - DNA Breaks, Double-Stranded
MH  - Female
MH  - Fibroblasts/metabolism/pathology/*radiation effects
MH  - Humans
MH  - Microscopy, Fluorescence
MH  - Middle Aged
MH  - Radiation Injuries/etiology/metabolism/pathology
MH  - Radiation Tolerance
MH  - Randomized Controlled Trials as Topic
MH  - Tumor Suppressor Protein p53/metabolism
OTO - NOTNLM
OT  - 53BP1
OT  - Breast cancer
OT  - Double-strand breaks
OT  - Individual radiosensitivity
OT  - Normal-tissue reaction
OT  - p53
EDAT- 2016/03/06 06:00
MHDA- 2016/08/30 06:00
CRDT- 2016/03/06 06:00
PHST- 2015/12/04 00:00 [received]
PHST- 2016/02/12 00:00 [revised]
PHST- 2016/02/23 00:00 [accepted]
PHST- 2016/03/06 06:00 [entrez]
PHST- 2016/03/06 06:00 [pubmed]
PHST- 2016/08/30 06:00 [medline]
AID - S0304-3835(16)30104-5 [pii]
AID - 10.1016/j.canlet.2016.02.036 [doi]
PST - ppublish
SO  - Cancer Lett. 2016 May 1;374(2):324-30. doi: 10.1016/j.canlet.2016.02.036. Epub
      2016 Mar 2.